Michael S. Sabel
Research Subjects
Michael S. Sabel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
David M. Lubman
Department of Surgery, University of Michigan Health Systems Biostatistics Core, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109
2 shared publicationsYashu Liu
Department of Surgery, University of Michigan Health Systems Biostatistics Core, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109
2 shared publicationsAlfred E. Chang
University of Michigan Health System
1 shared publicationDavid Kozminski
University of Michigan Health System
1 shared publication- Debashis Ghosh
Department of Biostatistics & Informatics, University of Colorado-Anschutz Medical Campus , Aurora, Colorado
1 shared publication Elizabeth M. Jaworski
Department of Radiation Oncology, University of Michigan, Ann Arbor, USA
1 shared publication
Latest Publications
- Open Access
- 11 August 2025
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 17 (1) , 1-8
Reshaping Breast Cancer Survivorship Through Expanding the Indications for the Omission of Radiation
Purpose of Review: As greater emphasis is placed on survivorship and long-term morbidity, more attention is being paid to de-escalation. This review examines areas where radiation may be safely omitted without compromising outcomes, thereby improving quality of life for breast cancer survivors. Recent Findings: Prospective randomized trials have identified populations that may safely avoid radiation after lumpectomy, although in many cases this may be a choice between radiation or anti-estrogen therapy. There is also retrospective and emerging prospective data identifying subsets of node positive patients undergoing mastectomy for whom radiation can be omitted, including low-risk patients and patients with complete responses to neoadjuvant therapy. Summary: Several retrospective and prospective studies have demonstrated that for subsets of patients, often based on newer prognostic assays, radiation may be safely omitted. This often involves shared decision making with the patient in a multidisciplinary fashion, as de-escalation of one modality is often predicated on the receipt of others.
- 11 August 2025
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 17 (1) , 1-8
Open AccessReshaping Breast Cancer Survivorship Through Expanding the Indications for the Omission of Radiation
Purpose of Review: As greater emphasis is placed on survivorship and long-term morbidity, more attention is being paid to de-escalation. This review examines areas where radiation may be safely omitted without compromising outcomes, thereby improving quality of life for breast cancer survivors. Recent Findings: Prospective randomized trials have identified populations that may safely avoid radiation after lumpectomy, although in many cases this may be a choice between radiation or anti-estrogen therapy. There is also retrospective and emerging prospective data identifying subsets of node positive patients undergoing mastectomy for whom radiation can be omitted, including low-risk patients and patients with complete responses to neoadjuvant therapy. Summary: Several retrospective and prospective studies have demonstrated that for subsets of patients, often based on newer prognostic assays, radiation may be safely omitted. This often involves shared decision making with the patient in a multidisciplinary fashion, as de-escalation of one modality is often predicated on the receipt of others.
- 8 October 2021
- Published by Springer Nature in Statistics in Biosciences
- Vol. 14 (3) , 363-379
A Weighted Sample Framework to Incorporate External Calculators for Risk Modeling
- 8 October 2021
- Published by Springer Nature in Statistics in Biosciences
- Vol. 14 (3) , 363-379
A Weighted Sample Framework to Incorporate External Calculators for Risk Modeling
- 3 April 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (7) , 2112-2119
Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older
While SLN biopsy is recommended for melanoma ≥1 mm in depth, its use among the elderly population is more controversial. We reviewed our experience at the University of Michigan with melanoma patients ≥75 years of age. A total of 952 melanoma patients ≥75 years of age from 1996 to 2011 were identified from our institutional review board-approved database. In addition to clinicopathologic features and outcome data, comorbidity data were collected to calculate the Charlson comorbidity index (CCI). Univariate and multivariate Cox regression analysis was performed to characterize predictors of outcome. Kaplan–Meier analysis was used to generate survival curves. Among 553 clinically node-negative patients with melanoma ≥1 mm in Breslow thickness, 213 had wide excision alone, whereas 340 had excision and SLN biopsy, with 83 (24 %) having a positive SLN. SLN biopsy was less likely with older age (p < 0.0001) and H&N location (p = 0.007), but not CCI. SLN involvement was associated with female gender [odds ratio (OR) 2.15, p = 0.009], Breslow thickness [OR 1.23/mm increase, p = 0.004], and satellitosis (OR 4.43, p = 0.004). Distant disease-specific survival was negatively associated with male gender (OR 1.5, p = 0.007), increasing age (OR 1.05/year, p < 0.001), increasing Breslow thickness (OR 1.07/year, p = 0.013), ulceration (OR 1.51, p = 0.004), a positive SLN (OR 2.61, p < 0.001), and not having a SLN biopsy (OR 1.72, p < 0.001). CCI did not predict worse disease-free or melanoma-specific survival. WLE and SLN biopsy was not only strongly prognostic, but compared with WLE alone was associated with improved outcome, even after factoring for age and comorbidities. If otherwise healthy, SLN biopsy should be strongly considered for this population.
- 3 April 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (7) , 2112-2119
Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older
While SLN biopsy is recommended for melanoma ≥1 mm in depth, its use among the elderly population is more controversial. We reviewed our experience at the University of Michigan with melanoma patients ≥75 years of age. A total of 952 melanoma patients ≥75 years of age from 1996 to 2011 were identified from our institutional review board-approved database. In addition to clinicopathologic features and outcome data, comorbidity data were collected to calculate the Charlson comorbidity index (CCI). Univariate and multivariate Cox regression analysis was performed to characterize predictors of outcome. Kaplan–Meier analysis was used to generate survival curves. Among 553 clinically node-negative patients with melanoma ≥1 mm in Breslow thickness, 213 had wide excision alone, whereas 340 had excision and SLN biopsy, with 83 (24 %) having a positive SLN. SLN biopsy was less likely with older age (p < 0.0001) and H&N location (p = 0.007), but not CCI. SLN involvement was associated with female gender [odds ratio (OR) 2.15, p = 0.009], Breslow thickness [OR 1.23/mm increase, p = 0.004], and satellitosis (OR 4.43, p = 0.004). Distant disease-specific survival was negatively associated with male gender (OR 1.5, p = 0.007), increasing age (OR 1.05/year, p < 0.001), increasing Breslow thickness (OR 1.07/year, p = 0.013), ulceration (OR 1.51, p = 0.004), a positive SLN (OR 2.61, p < 0.001), and not having a SLN biopsy (OR 1.72, p < 0.001). CCI did not predict worse disease-free or melanoma-specific survival. WLE and SLN biopsy was not only strongly prognostic, but compared with WLE alone was associated with improved outcome, even after factoring for age and comorbidities. If otherwise healthy, SLN biopsy should be strongly considered for this population.
- Open Access
- 19 October 2011
- Published by Wiley in International Journal of Proteomics
- Vol. 2011, 1-9
Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma
Better prognostic and predictive markers in melanoma are needed to select patients for therapy. We utilized a dual-lectin affinity chromatography and a natural protein microarray-based analysis to select a subproteome of target glycoproteins to profile serum antibodies against melanoma associated antigens that may predict nodal positivity. We identified 5 melanoma-associated antigens using this microarray coupled to mass spectrometry; GRP75, GRP94, ASAH1, CTSD and LDHB. We evaluated their predictive value for nodal status adjusting for age, gender, Breslow thickness, mitotic rate and ulceration using standard logistic regression. After adjustment, ASAH1, CTSD and LDHB were significantly negatively associated with nodal status (P = 0.0008) and GRP94 was significantly positively associated (P = 0.014). Our best multivariate model for nodal positivity included Breslow thickness, presence of serum anti-ASAH1, anti-LDHB or anti-CTSD, and presence of serum anti-GRP94, with an area under the ROC curve of 0.869. If validated, these results show promise for selecting clinically node negative patients for SLN biopsy. In addition, there is strong potential for glycoprotein microarray to screen serum autoantibodies that may identify patients at high risk of distant metastases or those likely or unlikely to respond to treatment, and these proteins may serve as targets for intervention.
- 19 October 2011
- Published by Wiley in International Journal of Proteomics
- Vol. 2011, 1-9
Open AccessClinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma
Better prognostic and predictive markers in melanoma are needed to select patients for therapy. We utilized a dual-lectin affinity chromatography and a natural protein microarray-based analysis to select a subproteome of target glycoproteins to profile serum antibodies against melanoma associated antigens that may predict nodal positivity. We identified 5 melanoma-associated antigens using this microarray coupled to mass spectrometry; GRP75, GRP94, ASAH1, CTSD and LDHB. We evaluated their predictive value for nodal status adjusting for age, gender, Breslow thickness, mitotic rate and ulceration using standard logistic regression. After adjustment, ASAH1, CTSD and LDHB were significantly negatively associated with nodal status (P = 0.0008) and GRP94 was significantly positively associated (P = 0.014). Our best multivariate model for nodal positivity included Breslow thickness, presence of serum anti-ASAH1, anti-LDHB or anti-CTSD, and presence of serum anti-GRP94, with an area under the ROC curve of 0.869. If validated, these results show promise for selecting clinically node negative patients for SLN biopsy. In addition, there is strong potential for glycoprotein microarray to screen serum autoantibodies that may identify patients at high risk of distant metastases or those likely or unlikely to respond to treatment, and these proteins may serve as targets for intervention.
- Open Access
- 11 October 2011
- Published by Hindawi Limited in International Journal of Proteomics
- Vol. 2011, 1-8
Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles
The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical. Genomic profiling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors, and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the field.
- 11 October 2011
- Published by Hindawi Limited in International Journal of Proteomics
- Vol. 2011, 1-8
Open AccessProteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles
The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical. Genomic profiling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors, and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the field.
- 1 March 2009
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 7 (3) , 281-289
Review of Evidence-Based Support for Pretreatment Imaging in Melanoma
When making a new diagnosis of melanoma, clinicians often obtain imaging studies to rule out clinically occult distant disease. These studies range from inexpensive tests, such as chest radiographs, to more expensive studies, such as PET/CT. The impetus for ordering these studies is usually the desire to identify potentially resectable distant disease, avoid surgery when curative resection is not possible, and assuage patient anxiety by showing that no evidence of distant disease is present. However, some detrimental aspects to these studies are less apparent, including cost and potential for false-positive findings. Although routine use seems reasonable, the true benefit of these studies depends on the probability of clinically occult disease being present, likelihood that disease will be detected with the available technology, and impact of earlier detection on outcome. Contrary to current practice patterns, available evidence suggests that preoperative imaging studies are associated with significant costs and minimal benefit in most patients with melanoma. This article reviews available literature on the role of pretreatment imaging in patients with newly diagnosed cutaneous melanoma.
- 1 March 2009
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 7 (3) , 281-289
Review of Evidence-Based Support for Pretreatment Imaging in Melanoma
When making a new diagnosis of melanoma, clinicians often obtain imaging studies to rule out clinically occult distant disease. These studies range from inexpensive tests, such as chest radiographs, to more expensive studies, such as PET/CT. The impetus for ordering these studies is usually the desire to identify potentially resectable distant disease, avoid surgery when curative resection is not possible, and assuage patient anxiety by showing that no evidence of distant disease is present. However, some detrimental aspects to these studies are less apparent, including cost and potential for false-positive findings. Although routine use seems reasonable, the true benefit of these studies depends on the probability of clinically occult disease being present, likelihood that disease will be detected with the available technology, and impact of earlier detection on outcome. Contrary to current practice patterns, available evidence suggests that preoperative imaging studies are associated with significant costs and minimal benefit in most patients with melanoma. This article reviews available literature on the role of pretreatment imaging in patients with newly diagnosed cutaneous melanoma.